2. GPCR/G Protein MAPK/ERK Pathway Apoptosis PI3K/Akt/mTOR
  3. Ras Apoptosis PI3K Akt p38 MAPK
  4. pan-KRAS-IN-5

pan-KRAS-IN-5 is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 strongly binds to and stabilizes KRAS rG4s, inhibits KRAS translation, and blocks the MAPK and PI3K-AKT pathways. pan-KRAS-IN-5 induces cell cycle arrest, prompts apoptosis in KRAS-driven cancer cells. pan-KRAS-IN-5 inhibits tumor growth and KRAS expression in KRAS-mutant xenograft. KRAS-IN-5 can be used for KRAS-driven cancer research.

For research use only. We do not sell to patients.

pan-KRAS-IN-5

pan-KRAS-IN-5 Chemical Structure

CAS No. : 3027172-23-9

Size Price Stock Quantity
5 mg Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks
10 mg Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks
25 mg Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks
50 mg Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks
100 mg   Get quote  
200 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

pan-KRAS-IN-5 Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

pan-KRAS-IN-5 is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 strongly binds to and stabilizes KRAS rG4s, inhibits KRAS translation, and blocks the MAPK and PI3K-AKT pathways. pan-KRAS-IN-5 induces cell cycle arrest, prompts apoptosis in KRAS-driven cancer cells. pan-KRAS-IN-5 inhibits tumor growth and KRAS expression in KRAS-mutant xenograft. KRAS-IN-5 can be used for KRAS-driven cancer research[1].

In Vitro

pan-KRAS-IN-5 (compound 15a) strongly binds to KRAS rG4s with KD values of 2.3 μM for utr-z and 0.9 μM for utr-1[1].
pan-KRAS-IN-5 (24 h) selectively kills KRAS-driven cancer cells, including MIA PaCa-2 (IC50 = 3.3 μM), PANC-1 (IC50 = 5.6 μM), HPAF-II (IC50 = 5.4 μM), SW620 (IC50 = 5.1 μM), HCT116 (IC50 = 4.0 μM), and NCI-H358 cells (IC50 = 4.8 μM), but shows no appreciable cytotoxicity in KRASWT glioblastoma cells or KRASWT normal cells[1].
Pan-KRAS-IN-5 (1.25-5.0 μM, 0-48 h) inhibits KRAS protein expression in PANC-1, MIA PaCa-2, and NCI-H358 cells without altering KRAS mRNA levels[1].
pan-KRAS-IN-5 (1.25-5.0 μM, 0-24 h) dose- and time-dependently inhibits the phosphorylation of MEK, ERK, AKT, and mTOR[1].
pan-KRAS-IN-5 (0.32-1.25 μM, 10 days) inhibits the proliferation of MIA PaCa-2 cells[1].
pan-KRAS-IN-5 (1.25-5.0 μM, 24 h) triggers a dose-dependent G2/M phase arrest in MIA PaCa-2 cells, and induces the cleavage of caspase 3 in KRAS mutant MIA PaCa-2 cancer[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

pan-KRAS-IN-5 Related Antibodies

Apoptosis Analysis[1]

Cell Line: MIA PaCa-2 cells
Concentration: 1.25, 2.5, and 5.0 μM
Incubation Time: 24 h
Result: Decreased Caspase-3 and increased CL- Caspase-3 leves in MIA PaCa-2 cells.

Cell Cycle Analysis[1]

Cell Line: MIA PaCa-2 cells
Concentration: 1.25, 2.5, and 5.0 μM
Incubation Time: 24 h
Result: Induced G2/M phase arrest in MIA PaCa-2 cells dose-dependently.

Cell Proliferation Assay[1]

Cell Line: MIA PaCa-2 cells
Concentration: 0.32, 0.63, and 1.25 μM
Incubation Time: 10 days
Result: Almost completely inhibited the proliferation of MIA PaCa-2 cells at the concentration of 1.25 μM.

Western Blot Analysis[1]

Cell Line: MIA PaCa-2 cells
Concentration: 1.25, 2.5, and 5.0 μM
Incubation Time: 0, 6, 12, and 24 h
Result: Reduced p-MEK, p-ERK, p-AKT and p-mTOR in MIA PaCa-2 cells in a dose-dependent manner.
Decreased p-MEK, p-ERK, p-AKT and p-mTOR in MIA PaCa-2 cells in a time-dependent manner.
In Vivo

pan-KRAS-IN-5 (2.5 and 5.0 mg/kg, i.p., every day for 18 days) inhibits tumor growth and reduces KRAS protein expression, but dose not effect total KRAS mRNA levels in a KRAS-mutant MIA PaCa-2 xenograft model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/C-nu/nu (4 weeks old) subcutaneously injected with MIA PaCa-2 cells[1]
Dosage: 2.5 and 5.0 mg/kg
Administration: i.p., every day for 18 days
Result: Inhibited tumor growth in a dose-dependent manner, with Tumor Growth Inhibition (TGI) of 62.0 % (2.5 mg/ kg) and 70.3 % (5.0 mg/kg).
Revealed no significant body weight loss in mice.
Exhibited no evident signs of toxicity in the anatomized viscera.
Molecular Weight

642.55

Formula

C31H36FIN4O2
CAS No.
Appearance

Solid

Color

Brown to black

SMILES

C[N+]1=C(/C=C/C2=CC3=CC=C(N(CC)CC)C=C3OC2=O)C=CC4=C1C=C(NCCN5CCCC5)C(F)=C4.[I-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

pan-KRAS-IN-5 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

pan-KRAS-IN-53027172-23-9RasApoptosisPI3KAktp38 MAPKPhosphoinositide 3-kinasePKBProtein kinase BTumorKRAS pan-KRASrG4s MAPK pathwayPI3K-AKT pathway KRAS-Driven Cancer Cellscycle arrest apoptosis MIA PaCa-2 cellspancreatic cancer cellscolorectal cancer cellslung cancer cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
pan-KRAS-IN-5
Cat. No.:
HY-163299
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.